| Exclusion Criteria: | 1) Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years.
2) Medical illness preventing the use of full-dose chemotherapy.
3) Evidence of bleeding diathesis or coagulopathy, INR > 1.5
4) Patients who require the use of warfarin sodium > 1 mg.
5) Previous medical or psychiatric illness that would prevent informed consent or limit survival to < 6 months.
6) Prior surgery to treat carcinoma of the cervix other than biopsy.
7) Patients who have undergone surgical debulking of pelvic or para-aortic nodes.
8) Patients with positive para-aortic disease
9) Previous pelvic radiation therapy including transvaginal irradiation to control bleeding.
10) Prior systemic chemotherapy.
11) Patients with active GI ulcers, GI bleeding, or active inflammatory bowel disease.
12) Pregnant, nursing or woman of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception.
13) Clinically significant cardiac disease (e.g., uncontrolled hypertension [blood pressure of > 160/90 mmHg on medication], history of myocardial infarction or unstable angina within 12 months of registration), New York Heart Association (NYHA) Class II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are not eligible.
14) Patients with a history of aneurysms, cerebrovascular accident (CVA) and arteriovenous malformations
15) Patients with arterial thromboembolic events, including transient ischemic attack (TIA), or clinically significant peripheral artery disease within 6 months of registration.
16) Tumor outside the pelvis.
17) Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to start of treatment, or anticipation of need for major surgical procedure during the course of the study.
18) Serious, non-healing wound, ulcer, or current healing fracture.
19) Patients with a history of any type of fistula (vesicovaginal, gastrointestinal, etc) or gastrointestinal perforation.
20) Intra-abdominal abscess within 6 months of study entry.
21) Patients who have had an organ transplant.
22) Patients with known hypersensitivity of Chinese hamster ovary cell products or other recombinant human antibodies.
23) Patients who are known to be HIV positive who have a CD4 cell count less than 350 cells/mm^3 within 21 days of registration; note, however, that HIV testing is not required for entry into this protocol. Excluding HIV positive patients with invasive cervical cancer and low CD4 cell counts is necessary because the treatments involved in this protocol may be significantly immunosuppressive. |